Risankizumab-rzaa (Skyrizi IV)

Provider Order Form rev. 7/30/2025



PATIENT INFORMATION	Referral Status:	□ New Re	eferral [☐ Updated Ord	er 🔲 Order Renewal
Patient Name:		DOB:		Patient Pho	ne:
Patient Address:			Patie	nt Email:	
Allergies:		□ NKDA	Weight (lbs/kg):	Height (in/cm):
Sex: ☐ M / ☐ F Date of Last Infusion:	Next Due Date	<u>:</u>	Prefer	red Location:	
DIAGNOSIS (Please provide ICD-10 code in space	e provided)				
☐ K50. : Crohn's Disease		: Ulcerative	Colitis		
Other:	Description:				
THERAPY ADMINISTRATION & DOSING ☑ Only IV induction dosing will be provided. Subcuta dosing WILL NOT be provided	neous [LABORATC ☐ Bilirubin, L ☐ Other:	FTs at wee		
or Crohn's Disease: Administer Risankizumab-rzaa (Skyrizi) 600mg IV over 1hour. lute in 100ml 0.9 NS or D5W		PRE-MEDICATION ORDERS ☐ Tylenol ☐ 500mg / ☐ 650mg PO ☐ Loratadine 10mg PO ☐ Pepcid 20mg ☐ PO / ☐ IVP			
For Ulcerative Colitis: ☐ Administer Risankizumab-rzaa (Skyrizi) 1200mg IV over 2 hours. Dilute in 250ml 0.9 NS or D5W		☐ Benadryl ☐ 25mg / ☐ 50mg ☐ PO / ☐ IVP☐ Solumedrol ☐ 40mg / ☐ 125mg IVP☐ Other:			
FREQUENCY (Choose one) ☑ Induction: week 0, week 4, and week 8		NURSING ✓ Hold infusi	on and no	tify provider for	;
ADDITIONAL ORDERS	H	● Elev ☑ Provide nu	rated LFTs or ersing care rity Reaction	or bilirubin per Nursing Pro	ctive infection or recent cedure, including Protocol and post-
PROVIDER INFORMATION					
Preferred Contact Name:	Preferred Contact Email:				
Ordering Provider:	Provider NPI:				
Referring Practice Name:		one:		Fax:	
Practice Address:	City	/ :	Sta	te:	Zip Code:
REQUIRED DOCUMENTATION CHECKLIST (Additional docume	ntation requ	uired for p	processing and	insurance approval)
Required Documentation: Patient demos, copy of the treatment failures or contraindications with immunous Required Labs: TB, Hep B, CRP, ESR, LFTs and Biliruk	osuppressants, bio	•	•	•	_
Provider Name (print) Pr	Provider Signature				Pate

Order valid for one year unless otherwise indicated. IV solutions/diluents may be substituted as allowed per manufacturer's instructions as necessitated by product availability.